Government-Owned Inventions; Availability for Licensing, 38710-38711 [2018-16838]
Download as PDF
<![CDATA[
38710
Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices
Planning Grant (R34) and Implementation
Cooperative Agreement (U01).
Date: August 28, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Louis A. Rosenthal, Ph.D.,
Scientific Review Officer Scientific Review
Program, Division of Extramural Activities,
Rm. 3G42B, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892–9834, (240) 669–5070,
rosenthalla@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 1, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–16789 Filed 8–6–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
daltland on DSKBBV9HB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Clinical and Translational Exploratory/
Developmental Studies.
Date: September 14, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin Arlington Gateway, 801
North Glebe Road, Arlington, VA 22203.
Contact Person: Robert S. Coyne, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W236, Bethesda, MD
20892–9750, 240–276–7684, coyners@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–7: NCI
VerDate Sep<11>2014
16:54 Aug 06, 2018
Jkt 244001
Clinical and Translational R21 and Omnibus
R03.
Date: September 27, 2018.
Time: 7:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Bethesda, MD
20892–9750, 240–276–5179, saejeong.kim@
nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group, Subcommittee
J—Career Development.
Date: October 11–12, 2018.
Time: 5:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard Bethesda, MD 20817.
Contact Person: Tushar Deb, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W624, Bethesda, MD 20892–9750,
240–276–6132, tushar.deb@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Molecular and Cellular Analysis
Technologies (IMAT).
Date: October 19, 2018.
Time: 8:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
2E908, Rockville, MD 20850.
Contact Person: Yasuko Furumoto, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W634, Bethesda, MD 20892–
9750, 240–276–5287, yasuko.furumoto@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; R25
Review.
Date: October 24, 2018.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W110, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Robert E. Bird, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W110, Bethesda, MD 20892–9750,
240–276–6344, birdr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Molecular Analysis Technologies (IMAT).
Date: November 1, 2018.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W634, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Yasuko Furumoto, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W634, Bethesda, MD 20892–
9750, 240–276–5287, yasuko.furumoto@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; UH2/UH3
Review.
Date: November 7, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W110, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Robert E. Bird, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W110, Bethesda, MD 20892–9750,
240–276–6344, birdr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 1, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–16784 Filed 8–6–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
SUMMARY:
E:\FR\FM\07AUN1.SGM
07AUN1
Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
This
notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
commercialization of results of
federally-funded research and
development.
Technology description follows.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2018–16838 Filed 8–6–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Albumin Binding Prostate Cancer
Treating Compositions
National Institutes of Health
The invention pertains to a
therapeutic agent that includes a
chemically conjugated residue derived
from (((R-)-1-carboxy-2mercaptoethyl)carbamoyl)-L-glutamic
acid that is further bound to an Evans
blue analog (EB). The EB analog
reversibly binds to circulating serum
albumin to provide a
radiopharmaceutical that retains affinity
and specificity to prostate specific
membrane antigen (PSMA; in this case
PSMA–617). PSMA is a surface
molecule shown to be specifically
expressed by prostate tumor cells.
PSMA expression levels correlate with
disease stage and with hormone
refractory cancers. Although most
PSMA expression appears to be
restricted to the prostate cancer, low
levels of expression can also be detected
in the brain, kidneys, salivary glands,
and small intestine. The antigen is also
shown to be expressed by neovascular
tumor vessels of multiple other cancers.
Inclusion of the Evans blue analog
promotes high internalization and
retention rates of the conjugated target
ligand, and therefore, higher
accumulation in PSMA positive tumors.
Labeling EB–PSMA–617 derivatives
with the therapeutic beta emitters, e.g.,
90Y, 86Y, and 177Lu gives rise to
improved tumor response and survival
rates.
Potential Commercial Applications:
• Cancer therapeutics
• Higher stability/Lower toxicity
Development Stage:
daltland on DSKBBV9HB2PROD with NOTICES
• Early stage
Inventors: Xiaoyuan Chen and Orit
Jacobson Weiss (both of NIBIB).
Intellectual Property: HHS Reference
No. E–054–2018/0; U.S. Provisional
Patent Applications 62/633,648 filed
February 22, 2018.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
VerDate Sep<11>2014
16:54 Aug 06, 2018
Jkt 244001
Dated: July 20, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Barry Buchbinder, Ph.D., 240–627–
3678; barry.buchbinder@nih.gov.
Licensing information and copies of the
U.S. patent application listed below
may be obtained by communicating
with the indicated licensing contact at
the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
MD 20852; tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Self-Assembling Insect Ferritin
Nanoparticles for Display of Coassembled Trimeric Antigens
Description of Technology
Antigens on the surface of virus
particles are displayed in a regular,
repetitive pattern which facilitates B
cell activation. Presenting trimeric
antigens on engineered particles that
mimic the geometric patterns observed
for native viral proteins can lead to an
improved host antibody response.
Self-assembling globular ferritin
nanoparticles have previously been
used to display multiple copies of a coassembled trimeric antigen to the
immune system. However, prior ferritin
nanoparticle technologies only permit a
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
38711
random co-assembly of diverse trimeric
antigens, and therefore cannot guarantee
the pattern and ratio of diverse trimeric
antigens on a single ferritin
nanoparticle.
Researchers at the Vaccine Research
Center (VRC) of the National Institute of
Allergy and Infectious Diseases are
developing novel recombinant ferritin
nanoparticles that are based on insect
ferritin proteins, and that have been
engineered to display two different
trimeric antigens in a defined ratio and
geometric pattern. This system has been
tested with antigens derived from HIV–
1 envelope (Env) and influenza
hemagglutinin (HA). Interestingly, when
guinea pigs are immunized with ferritin
nanoparticles displaying two different
trimeric antigens, induced B cells could
simultaneously recognize both trimeric
antigens, thus leading to an immune
response with improved neutralization
breadth.
This technology can be used as a
platform for multimerized display of
trimeric antigens such as viral type I
fusion glycoproteins, and may be
applied to many high-priority vaccine
targets, such as HIV–1, influenza,
respiratory syncytial virus,
parainfluenza viruses, and
coronaviruses.
Potential Commercial Applications:
• Platform for multimerized
immunogen presentation and vaccine
design.
• Vaccines for pathogens that use
genetic diversity to escape the immune
response.
Competitive Advantages:
• Particles have equal fractions of two
different antigens in a specific
configuration on the nanoparticle
surface (unlike regular ferritin used
previously)
• Designed particles have a geometry
that allows for attachment of trimeric
antigens (unlike the native insect
ferritin).
Development Stage:
• In vivo testing (rodents).
Inventors: Peter Kwong (NIAID),
Ivelin Georgiev (NIAID), Michael
Gordon Joyce (NIAID), Masaru Kanekiyo
(NIAID), Aliaksandr Druz (NIAID),
Ulrich Baxa (NIAID), Joseph Van Galen
(NIAID), Rita Chen (NIAID), Cheng
Cheng (NIAID), John Mascola (NIAID),
Yaroslav Tsybovsky (Leidos Biomedical
Research, Inc), Yongping Yang (NIAID),
Paul Thomas (NIAID), Barney Graham
(NIAID).
Publications: Georgiev, Ivelin S., et
al., ACS Infectious Diseases (2018) 4 (5),
788–796.
Intellectual Property: HHS Reference
Number E–270–2015: U.S. Patent
Application No. 62/355,212 filed 06/27/
E:\FR\FM\07AUN1.SGM
07AUN1
]]>Agencies
[Federal Register Volume 83, Number 152 (Tuesday, August 7, 2018)]
[Notices]
[Pages 38710-38711]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16838]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda,
MD 20892-2479; telephone: 301-402-5579. A signed
[[Page 38711]]
Confidential Disclosure Agreement may be required to receive any
unpublished information.
SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve commercialization of results of
federally-funded research and development.
Technology description follows.
Albumin Binding Prostate Cancer Treating Compositions
The invention pertains to a therapeutic agent that includes a
chemically conjugated residue derived from (((R-)-1-carboxy-2-
mercaptoethyl)carbamoyl)-L-glutamic acid that is further bound to an
Evans blue analog (EB). The EB analog reversibly binds to circulating
serum albumin to provide a radiopharmaceutical that retains affinity
and specificity to prostate specific membrane antigen (PSMA; in this
case PSMA-617). PSMA is a surface molecule shown to be specifically
expressed by prostate tumor cells. PSMA expression levels correlate
with disease stage and with hormone refractory cancers. Although most
PSMA expression appears to be restricted to the prostate cancer, low
levels of expression can also be detected in the brain, kidneys,
salivary glands, and small intestine. The antigen is also shown to be
expressed by neovascular tumor vessels of multiple other cancers.
Inclusion of the Evans blue analog promotes high internalization and
retention rates of the conjugated target ligand, and therefore, higher
accumulation in PSMA positive tumors. Labeling EB-PSMA-617 derivatives
with the therapeutic beta emitters, e.g., 90Y, 86Y, and 177Lu gives
rise to improved tumor response and survival rates.
Potential Commercial Applications:
Cancer therapeutics
Higher stability/Lower toxicity
Development Stage:
Early stage
Inventors: Xiaoyuan Chen and Orit Jacobson Weiss (both of NIBIB).
Intellectual Property: HHS Reference No. E-054-2018/0; U.S.
Provisional Patent Applications 62/633,648 filed February 22, 2018.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
[email protected].
Dated: July 20, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-16838 Filed 8-6-18; 8:45 am]
BILLING CODE 4140-01-P
